Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)TransplantationDiseaseAcute Lymphoblastic LeukaemiaAcute Myeloid LeukemiaMyelodysplastic NeoplasmsStem Cell Transplantation, AllogeneicSubgroupICD10C91.0-C92.0-C92.5-C92.6-C92.7-C92.8-C92.9-C93.0-D46.-MeSHHematopoietic Stem Cell TransplantationMyelodysplastic SyndromesPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaTransplantation ConditioningSequenceChemotherapyChemo-substanceAzacitidineLenalidomideChemo-substanceAzacitidineLenalidomideChemo-substanceAzacitidineLenalidomideChemo-substanceAzacitidineLenalidomideNo. Substances12 RadiotherapySupportive therapySupportive substanceAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleDexamethasoneDimetindenFluconazoleFludarabineFosaprepitantGranisetronLevetiracetamMelphalanMethylprednisoloneParacetamolPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleDexamethasoneDimetindenFluconazoleFludarabineFosaprepitantGranisetronLevetiracetamMelphalanMethylprednisoloneParacetamolPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleDexamethasoneDimetindenFluconazoleFludarabineFosaprepitantGranisetronLevetiracetamMelphalanMethylprednisoloneParacetamolPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirSupportive substanceAnti-thymocyte Globulin (Rabbit)Balanced Crystalloid SolutionBusulfanCarmustineCiprofloxacinCotrimoxazoleDexamethasoneDimetindenFluconazoleFludarabineFosaprepitantGranisetronLevetiracetamMelphalanMethylprednisoloneParacetamolPosaconazoleThiotepaTreosulfanUrsodeoxycholic acidValaciclovirNo. Substances310111216Protocol classificationTherapy classificationalternativecurrent standardIntensityKonditionierung, intensitäts- oder dosisreduziert (RIC)Konditionierung, myeloablativ (MAC)Konditionierung, nicht-myeloablativ (NMA)Standard doseTherapy indicationRelapse therapyTherapy phaseallogene StammzelltransplantationTherapy intentioncurativecurative or palliativepalliativeRisksBleedingCardiotoxicityEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHepatotoxicityHyperbilirubinemiaInfectionsNeurotoxicityNeutropeniaPainPneumoniaRenal FailureSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorAnand S Beelen DWCiurea SOCraddock CEstey EKornblit BLübbert MMarks RPlatzbecker URambaldi ASchroeder TShimoni ASolomon SRDiseaseAML, 40-65 Jahre, ECOG 0-2, < 5% BlastenAML, MDS, CML, NHL, ungeeignet für konventionelle intensive KonditionierungAML- oder CMML-Rezidiv nach allogener StammzelltranplantationAML- oder MDS-Rezidiv nach allogener StammzelltranplantationAML/ALL/MDS, allogene SCTAML/MDS, 18-65 Jahre, < 5% BlastenAML/MDS, 18-70 Jahre, AML in kompletter hämatologischer Remission (unter 5% Blasten) oder MDS (unter 20% Blasten), HCT-CI Score über 2AML/MDS, ALL, allogene StammzelltransplantationAML/MDS, ALL, NHL, Stammzelltransplantation mit NabelschnurblutAML/MDS, allogene StammzelltransplantationAML/MDS, ungeeignet für konventionelle intensive KonditionierungAML/MDS, unter 55 JahreDrohendes AML- oder MDS-Rezidiv nach allogener Stammzelltranplantation (Spenderchimärismus <80%)OriginAlbert-Ludwigs University Medical Center, Freiburg, GermanyCarl Gustav Carus Technical University of Dresden, Dresden, Germany, RELAZA trialClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WashingtonDepartment of Haematology and Oncology, Albert-Ludwigs University Medical Center, FreiburgDivision Hematology and Oncology, University of Freiburg Medical Center, Freiburg, GermanyDivision of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Duke University, Durham, North CarolinaHematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, ItalyOncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, GermanyThe Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GeorgiaThe Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, IsraelThe University of Texas M. D. Anderson Cancer Center, Houston, USAUniversity of Birmingham, Birmingham, United KingdomUniversity of Texas MD Anderson Cancer Center, Houston, USAWest German Cancer Centre, University of Duisburg-Essen, Essen, GermanyProtokolle in Überarbeitung 14 protocols foundAzacitidine 100, Acute Myeloid Leukemia, and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation (PID2302 V1.0)Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation, Variant 1 (PID2320 V1.0)Azacitidine 75 / Lenalidomide 25, Acute Myeloid Leukemia and Myelodysplastic Syndrome following Allogeneic Stem Cell Transplantation (PID827 V1.2)Azacitidine 75, Acute Myeloid Leukemia, and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation (PID2327 V1.0)Fludarabine 30 / Carmustine 150 / Melphalan 110, Allogeneic Stem Cell Transplantation, RIC (PID880 V1.0)Fludarabine 30 / Carmustine 200 / Melphalan 140, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, RIC (PID1705 V1.0)Fludarabine 30 / Melphalan 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, RIC (PID3225 V1.0)Fludarabine 30 / TBI 12, Allogeneic Stem Cell Transplantation, MAC (PID3219 V1.0)Fludarabine 30 / TBI 2, Allogeneic Stem Cell Transplantation, NMA (PID3222 V1.0)Fludarabine 30 / Treosulfan 10, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, MAC (PID1706 V1.0)Fludarabine 40 / Busulfan 0.8 / Anti-thymocyte Globulin (Rabbit) (0.5/2.0/2.5), Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation, MAC (PID885 V1.0)Fludarabine 40 / Busulfan 3.2 / Anti-thymocyte Globulin (Rabbit) 10, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, MAC (PID881 V1.0)Melphalan 140 / Thiotepa 10 / Fludarabine 40, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Allogeneic Stem Cell Transplantation, RIC (PID1738 V1.0)Thiotepa 5 / Fludarabine 40 / TBI 13.5, Allogeneic Stem Cell Transplantation, MAC (PID3224 V1.0)
